Journal article icon

Journal article

The efficacy of antimalarial monotherapies, sulphadoxine-pyrimethamine and amodiaquine in East Africa: implications for sub-regional policy.

Abstract:

Between 1998 and 2001, Kenya, Uganda, Tanzania, Zanzibar, Rwanda and Burundi changed antimalarial drug policy, in the face of widespread chloroquine resistance. The new first-line treatment is either sulphadoxine-pyrimethamine (SP) monotherapy, or a combination of SP with either chloroquine or amodiaquine. Two national malaria control programmes, Burundi and Zanzibar, have decided upon amodiaquine-artesunate as their first-line treatment, although SP will continue to fill this role until the ...

Expand abstract
Publication status:
Published

Actions


Access Document


Authors


East African Network for Monitoring Antimalarial Treatment (EANMAT) More by this author
Journal:
Tropical medicine and international health : TM and IH
Volume:
8
Issue:
10
Pages:
860-867
Publication date:
2003-10-05
DOI:
EISSN:
1365-3156
ISSN:
1360-2276
URN:
uuid:63e28e64-167a-4394-9711-8b32f44c3a90
Source identifiers:
38750
Local pid:
pubs:38750

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP